Table 1. Immune checkpoint blockade.
| Compound | Target |
|---|---|
| Ipilimumab | CTLA4 |
| Tremelimumab | CTLA4 |
| Nivolumab | PD-1 |
| Pembrolizumab | PD-1 |
| BMS-936559 | PD-L1 |
| MPDL3280A | PD-L1 |
| MEDI4736 | PD-L1 |
| Bec2 | GD3 |
| Bevacizumab | VEGF |
| Urelumab | CD137 |
| TRX518 | GITR |
| Anti-OX40 | OX40 |
| Anti-CD40 | CD40 |
| Solitomab | EpCAM |
| Anti-CD133 | CD133 |
| Lirilumab | KIR |
| BMS-9896016 | LAG-3 |
| Racotumomab | N-glycolil-GM3 ganglioside |
CTLA4, cytotoxic T-lymphocyte antigen 4; PD-1, programmed death receptor 1; PD-L1, programmed death ligand 1; VEGF, vascular endothelial growth factor; GITR, glucocorticoid-induced tumor necrosis factor receptor; EpCAM, epithelial cell adhesion molecule; KIR, killer cell immunoglobulin-like receptor; LAG-3, lymphocyte-activation gene 3.